Based on a theory advanced by the late Jonas Salk, Remune is produced from HIV irradiated and treated with chemicals to kill it and remove a protein the virus uses to enter cells. However, Remune has been in clinical trials for years with modest results to show for it, said John McCamant, editor of the Berkeley-based Medical Technology Stock Letter. I'm not sure what you'd do with the data at this point. The U. S. Food and Drug Administration typically doesn't accept the results of a subset in a clinical trial, unless further studies are conducted that confirm a response, McCamant said. A short squeeze is when short sellers have to buy stock back to cover their positions.
Short sellers borrow stock and sell it in anticipation of buying it back at a lower price.
However, if the stock price rises, the short sellers have to buy it back anyway, putting even more upward pressure on the price. Remune is being developed by Immune Response in combination with Agouron Pharmaceuticals, a La Jolla-based subsidiary of Pfizer. Agouron spokesperson Kim Simon said the company as a rule does not comment on clinical work by its partner, but remains committed to jointly developing Remune.